Skip to main content
. 2019 Apr 23;10:1856. doi: 10.1038/s41467-019-09834-2

Table 1.

Subject demographic and clinical annotation in the discovery and validation cohorts

Variable Discovery cohort (n = 30) Validation cohort (n = 20) P value
Average # biopsies/subject 6.6 (5.7) 5.25 (2.9) 0.3
Average # bronchoscopies/subject 3.1 (1.6) 2.5 (0.7) 0.08
Average time between bronchoscopies (days) 348.6 (197.5) 366.8 (208.3) 0.69
Male 15/30 (50) 12/20 (60) 0.81
White 27/30 (90) 17/20 (85) 1
Age (at baseline clinical visit) 58.8 (7.6) 58.7 (8.3) 0.97
Ever smoker (at baseline clinical visit) 29/30 (96.7) 19/20 (95) 1
Pack-years (at baseline clinical visit) 49.8 (22.1) 41.3 (20.7) 0.17
Prior history of lung cancer 21/30 (70) 12/20 (60) 0.82
    Prior history of LUSC 5/30 (16.7) 5/20 (25) 0.73
COPD (FEV1/FVC ≤ 0.7, at baseline clinical visit) 17/27 (63.0) 8/18 (44.4) 0.61
    GOLD 1 (FEV1%> 80) 2/27 (7.4) 2/18 (11.1) 1
    GOLD 2 (FEV1% < 80 and > 50) 12/27 (44.4) 5/18 (27.8) 0.56
    GOLD 3 (FEV1% < 50 and > 30) 3/27 (11.1) 1/18 (5.6) 1
Occupational asbestos 13/30 (43.3) 9/20 (45) 1
Occupational high-risk job 14/30 (46.7) 12/20 (60) 0.62

Statistical tests between the discovery and validation cohorts were performed using two-sided Fisher’s exact tests for categorical variables and two-sided Student’s t-tests for continuous variables. Percentages are reported for categorical variables and mean and standard deviations are reported for continuous variables. Source data are provided as a Source Data file

HHS Vulnerability Disclosure